Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
March 14, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present a quantitative systems pharmacology (QSP) model for predicting...
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
March 03, 2023 16:05 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of...
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 28, 2023 22:36 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a...
Travere Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2023 16:01 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023 16:01 ET
|
Travere Therapeutics, Inc.
Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN) European...
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023 16:04 ET
|
Travere Therapeutics, Inc.
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial...
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
February 16, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at Upcoming Investor Conferences
February 08, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: SVB Securities...